Nucleic acid polymers: much-needed hope for hepatitis D?

Affiliations

¹ Department of Pathology and Immunology, University of Geneva, Geneva 1211, Switzerland. Electronic address: dulce.alfaiate@unige.ch.
² Divisions of Gastroenterology and Hepatology and Clinical Pathology, University Hospitals of Geneva, Geneva, Switzerland.

Comment

Dulce Alfaiate et al. Lancet Gastroenterol Hepatol. 2017 Dec.

. 2017 Dec;2(12):841-842.

doi: 10.1016/S2468-1253(17)30292-3. Epub 2017 Sep 28.

¹ Department of Pathology and Immunology, University of Geneva, Geneva 1211, Switzerland. Electronic address: dulce.alfaiate@unige.ch.
² Divisions of Gastroenterology and Hepatology and Clinical Pathology, University Hospitals of Geneva, Geneva, Switzerland.

No abstract available

Comment on

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. Bazinet M, et al. Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28. Lancet Gastroenterol Hepatol. 2017. PMID: 28964701 Clinical Trial.